Comparison
3 Methylglutaconic Aciduria Type Viia C5676967 vs 17q24 2 Microdeletion Syndrome C5680185
Clinical comparison between 3 Methylglutaconic Aciduria Type Viia and 17q24 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type Viia C5676967
A rare inherited metabolic disorder affecting mitochondrial function. It typically appears in infancy with developmental delay, movement problems, and muscle weakness. Management focuses on supportive care and addressing specific symptoms.
17q24 2 Microdeletion Syndrome C5680185
A rare genetic disorder caused by deletion of genetic material on chromosome 17. Individuals may have developmental delays, facial features, and other medical issues. Care is supportive and multidisciplinary.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type Viia C5676967
0-2
17q24 2 Microdeletion Syndrome C5680185
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type Viia C5676967
severe
17q24 2 Microdeletion Syndrome C5680185
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type Viia C5676967
Chronic
17q24 2 Microdeletion Syndrome C5680185
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type Viia C5676967
No
17q24 2 Microdeletion Syndrome C5680185
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17q24 2 Microdeletion Syndrome C5680185
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type Viia C5676967
metabolic
17q24 2 Microdeletion Syndrome C5680185
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-viia-C5676967 and 17q24-2-microdeletion-syndrome-C5680185 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17q24 2 Microdeletion Syndrome C5680185 | Discriminating power |
|---|---|---|---|
| Developmental delay | Typically begins in infancy and may accompany movement problems and weakness. | May occur with variable congenital features; timing is not fully established. | Low |
| Movement and muscle findings | Movement problems and muscle weakness are described as typical. | Not specifically established by the supplied description. | Moderate |
| Facial or structural features | Not established as characteristic from the supplied source. | Facial features and other medical issues may be present. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type Viia C5676967 when
Infant with developmental delay plus movement problems or weakness
This pattern aligns with the described mitochondrial metabolic presentation.
Moderate
Suspected inherited metabolic disease
The condition is categorized as a rare inherited metabolic disorder.
High
Need to distinguish an abnormal metabolite result from a diagnosis
A suggestive biochemical result still requires confirmatory clinical and genetic interpretation.
High
Choose 17q24 2 Microdeletion Syndrome C5680185 when
Developmental delay with congenital or facial features
This better matches the described chromosomal microdeletion syndrome.
Moderate
Suspected chromosomal copy-number disorder
The condition is defined by deletion of material on chromosome 17.
High
Broad congenital evaluation without a metabolic clue
A congenital genetic category is more consistent than a primary metabolic diagnosis.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type Viia C5676967 | 17q24 2 Microdeletion Syndrome C5680185 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | May show abnormal 3-methylglutaconic acid; no cutoff is established here. | No characteristic organic-acid abnormality is established. | An abnormal result supports metabolic evaluation but is not itself a diagnosis. |
| Chromosomal microarray | Not expected to define this metabolic condition. | May identify a 17q24.2 deletion when clinically suspected. | A detected deletion needs laboratory and clinical correlation. |
| Disease-specific genetic testing | May be used to investigate the suspected inherited metabolic disorder. | May confirm or refine a chromosomal deletion finding. | Gene or region selection should follow specialist assessment. |
Prognosis comparison
3 Methylglutaconic Aciduria Type Viia C5676967
- Outcome
- Described as severe, but individual outcome is not established.
- Factors
- Infancy onset, developmental delay, movement problems, and weakness may influence needs.
17q24 2 Microdeletion Syndrome C5680185
- Outcome
- Described as moderate, with variable and incompletely defined outcomes.
- Factors
- Developmental delay, facial features, and other medical issues may affect course.
Time frame: Both are chronic; precise milestones or survival data are not established.
Prognosis requires individualized clinician interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Neuromotor impairment | Movement problems and muscle weakness are described. Not specifically established, although developmental delay may occur. Severity and complications vary; exact risks are not established. |
| Associated congenital issues | Not established from the supplied description. Other medical issues may accompany the deletion. The range of issues is not defined here. |
| Care complexity | Supportive care targets specific symptoms. Supportive multidisciplinary care is described. Neither description establishes a standard treatment regimen. |
Patient education highlights
- HighDiagnosis versus test result
An abnormal laboratory or genetic finding needs clinician confirmation and does not automatically establish the diagnosis.
- HighSupportive care
Both conditions are managed supportively; no doses or disease-specific treatments are established here.
- MediumInheritance and family questions
Family implications differ by condition and should be discussed with a genetics clinician.